Dr. Peters Invest GmbH was established in October 2019. As the new marketing organisation within Dr. Peters Group, it assumed all responsibilities from Dr. Peters Asset Invest GmbH & Co. KG.
Under the notice of authorisation dated 20 August 2020, Dr. Peters Invest GmbH is permitted to provide investment broking (section 1 (1a) sentence 2 no. 1 of the German Banking Act (Kreditwesengesetz)), investment advice (section 1 (1a) sentence 2 no. 1a of the German Banking Act) and placement business (section 1 (1a) sentence 2 no. 1c of the German Banking Act). Dr. Peters Invest GmbH commenced trading as a financial services institution as of 1 September 2020.
We attach great importance to addressing customers’ concerns and complaints quickly and efficiently. To this end, we have established a central point of contact for investors.
Dr. Peters Invest GmbH
Authorised under section 32 (1) sentence 1 of the German Banking Act
Registered office: Dortmund, Stockholmer Allee 53
Registry court: Amtsgericht Dortmund
Company registration number: HRB 31295
VAT registration number: DE326636468
Managing Directors: Vanessa Meinker, Sven Mückenheim
Competent supervisory authority: BaFin (Federal Financial Supervisory Authority), Bonn or Frankfurt office; Deutsche Bundesbank, North Rhine-Westphalia regional office
The status information on Dr. Peters Invest GmbH is available HERE.
The requirements for remuneration policies applicable within Dr. Peters Invest GmbH, in conformity with the requirements for an institution within the meaning of the German Banking Act, were established at European Union level by Article 92 et seq. of Directive 2013/36/EU (CRD IV) and Regulation (EU) No 575/2013 (the CRR).
At national level, the requirements of CRD IV have been transposed into German law by the Remuneration Ordinance for Institutions (Institutsvergütungsverordnung) and the German Banking Act (Kreditwesengesetz).
Dr. Peters Invest GmbH does not currently meet the criteria for a significant institution within the meaning of the Remuneration Ordinance for Institutions.
The remuneration policies of Dr. Peters Invest GmbH are designed to achieve the aims laid down in the institution’s business and risk strategies (section 4 of the Remuneration Ordinance for Institutions). They do not provide incentives to assume risks that are inconsistent with the risk profile, the articles of association or the organisational guidelines of the institution within the meaning of the German Banking Act. The remuneration policies are geared to the business model as well as to long-term performance and avoid false incentives for employees who make risk assumption decisions.
Dr. Peters Invest GmbH discloses commissions, using them to improve the quality of the financial services and to ensure the proper functioning of its operations.
Variable remuneration is only paid to managing directors and to identified risk takers within the meaning of section 18 of the Remuneration Ordinance for Institutions if it is ensured that no negative incentives are created and that there is adequate capitalisation within the meaning of section 4 of the Ordinance. As a matter of policy, bonus payments are only made if they incentivise customer gains/benefits and the application of a consistent risk strategy in organisational and operational processes as key corporate objectives. The nature and amount of bonus payments are determined on the basis of the advancement of corporate objectives and documented in a performance appraisal.
In the provision of investment services or ancillary investment services, Dr. Peters receives remuneration and inducements from third parties where permissible under the provisions of the Securities Trading Act (Wertpapierhandelsgesetz). Irrespective of whether they comprise cash or non-cash benefits, we ensure that these do not conflict with our customers’ interests and that they are used to maintain or further improve the quality of the services we provide.
For any institution providing customers with both marketing and investment services, it is not always possible to rule out that conflicts of interest will arise. In accordance with the provisions of the Securities Trading Act, we therefore point to the following information regarding our extensive precautions for dealing with such conflicts of interest.
INFORMATION ON INDUCEMENTS.